Action Against AMD have partnered with artificial intelligence company BenevolentAI to uncover the mysteries of age-related macular degeneration.
Artificial intelligence has essentially been used to identify existing drugs that may reduce sight loss from macular degeneration.
The initial results from the artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, which is known to be the leading cause of sight loss.
This article highlights the scope for developing therapeutics with new innovative, alternative approaches. The current trillion dollars pharmaceutical industry is in peril where the current drug development pipeline is slow, inefficient and incapable of being extended to multi-combination drug therapies as well as minimally focused on prevention. The complex modeling of diseases and biological functions has been limited because of the inability to integrate large scale molecular pathways.
Watch this Video to understand how recent advances provide breakthrough technology for doing scalable modeling of complex molecular systems to dramatically accelerate drug discovery and development.